9/20/2021 8:34:57 AM
Gilead Sciences Announces Upcoming Presentation Of New Data From Virology Research And Development Programs
9/16/2021 7:06:11 AM
Gilead Sciences Announces New Data From Phase 3 ASCENT Study Of
Trodelvy
9/13/2021 8:34:04 AM
Gilead Sciences To Present Data At ESMO Congress 2021 Reinforcing Practice-changing Potential Of Trodelvy
8/5/2021 8:41:03 AM
Kite And Appia Bio Announce Collaboration To Research And Develop Allogeneic Cell Therapies For Cancer
8/4/2021 7:06:44 AM
BioNTech Closes Acquisition Of Kite's Neoantigen TCR Cell Therapy R&D Facility In Gaithersburg, Maryland
8/3/2021 11:02:25 AM
Gilead Sciences Announces More Than $200 Mln Endowment To Gilead Foundation
7/29/2021 5:19:20 PM
Gilead Sciences Q2 EPS $1.21 Vs. Loss $2.66 Year Ago
7/29/2021 5:01:57 PM
Gilead Sciences Inc. (GILD) Has Raised Its FY21 Revenue Estimate To $24.4 - $25.0 Bln From $23.7 - $25.1 Bln
7/19/2021 8:03:08 AM
BioNTech To Buy Kite's Neoantigen TCR Cell Therapy R&D Platform And
Manufacturing Facility In Gaithersburg
6/28/2021 8:35:21 AM
Kite Says ZUMA-7 Study Meets Primary Endpoint Of Event-free
survival, Secondary Endpoint Of Objective Response Rate
6/24/2021 9:07:15 AM
Gilead Announces Interim Results From Phase 2b And Phase 3
clinical Trials Evaluating Hepcludex